NASDAQ:VPHM ViroPharma (VPHM) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free VPHM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ViroPharma alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About ViroPharma Stock (NASDAQ:VPHM)ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.Read More Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. VPHM Stock News HeadlinesSeptember 2, 2023 | thestreet.comHAE: Biotech's Latest Orphan-Drug RaceAugust 24, 2023 | thetimes.co.ukDriven out of Eden, from Paradise Lost by John Milton (1608 74)March 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… April 10, 2023 | thestreet.comViroPharma Stock Hits New 52-Week High (VPHM)May 2, 2022 | thestreet.comMarket Preview: A Huge MistakeApril 30, 2022 | fool.comNo Swelling Sales HereJanuary 18, 2022 | thestreet.comDespite Nasdaq's Record, Market Players Eye Trends UneasilySee More Headlines Receive VPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViroPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VPHM CUSIP92824110 CIK946840 Webwww.viropharma.com Phone+1-610-4587300FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report VPHM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of ViroPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ViroPharma investors own include Caterpillar (CAT), Johnson & Johnson (JNJ), Pharmacyclics (PCYC), Boeing (BA), Bank of America (BAC), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Costco Wholesale (COST) and Deere & Company (DE). This page (NASDAQ:VPHM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ViroPharma Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.